Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Shared genetic architecture between metabolic traits and Alzheimer's disease: a large-scale genome-wide cross-trait analysis.
|
30805717 |
2019 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Increasing evidence emphasizes the protective role of Eph receptors in synaptic function in the pathological development of Alzheimer's disease (AD); however, their roles in the regulation of hippocampal astrocytes remain largely unknown.
|
30899407 |
2019 |
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The Eph tyrosine kinase receptors expressed in neurons are important in many contexts during neural-circuit formation, such as axon outgrowth, axon guidance, and synaptic formation, and have been suggested to be involved in neurodegenerative disorders, including amyotrophic lateral sclerosis and Alzheimer's disease.
|
29363583 |
2018 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We think that rs11767557 may modify the expression of nearby genes such as EPHA1 and further cause AD risk.
|
29332039 |
2018 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
GWAS on family history of Alzheimer's disease.
|
29777097 |
2018 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
|
28199971 |
2017 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNPs) in and near ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, complement receptor 1 (CR1), EPHA1, EXOC3L2, FERMT2, HLA cluster (DRB5-DQA), INPP5D, MEF2C, MS4A cluster (MS4A3-MS4A6E), NME8, PICALM, PTK2B, SLC24A4, SORL1, and ZCWPW1 have been associated with Alzheimer's disease (AD) in large meta-analyses.
|
27005436 |
2016 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study suggests EPHA1 (rs11771145) interferes with the pathological alteration of the hippocampus and the lateral occipitotemporal and inferior temporal gyri throughout the AD process, leading to a lower risk of AD.
|
25182741 |
2015 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here we review recent discoveries on Eph receptors-mediated protection against Aβ oligomers neurotoxicity as well as their potential as therapeutic targets in AD pathogenesis.
|
25193466 |
2015 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our method identified that two genes, CR1 and EPHA1, demonstrate significant interactions with CVD risk factors on hippocampal volume, suggesting that CR1 and EPHA1 may play a role in influencing AD-related neurodegeneration in the presence of CVD risks.
|
25600633 |
2015 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Five genomewide association studies (GWAS) in white populations have recently identified and confirmed 9 novel Alzheimer's disease (AD) susceptibility loci (CLU, CR1, PICALM, BIN1, ABCA7, MS4A gene cluster, CD2AP, CD33, and EPHA1).
|
23232270 |
2013 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Several loci previously associated with Alzheimer disease but not reaching significance in genome-wide analyses were replicated in gene-based analyses accounting for linkage disequilibrium between markers and correcting for number of tests performed per gene (CR1, BIN1, EPHA1, CD33; 0.0005 < empirical P < .001).
|
23571587 |
2013 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
CTD_human |
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
|
21460841 |
2011 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
CTD_human |
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.
|
21460840 |
2011 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.
|
21460840 |
2011 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that alterations in Eph receptors may play a role in synaptic dysfunction in the hippocampus leading to cognitive impairment in a model of AD.
|
19542617 |
2009 |
Colorectal Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Colorectal cancers express the EphrinB ligand and its Eph receptors at significantly higher levels than numerous other cancer types, supporting Eph signaling inhibition as a potential new strategy for the broad treatment of colorectal carcinoma.
|
31545551 |
2019 |
Colorectal Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Dysregulation of erythropoietin-producing hepatoma (Eph) proteins in human cancers is extensively documented but not clear in colorectal cancer (CRC).
|
30538561 |
2018 |
Colorectal Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Our cohort screening data showed that in patients with colorectal cancer, low expression of EPHA1 gene is correlated with a remarkably reduced survival.
|
26977017 |
2016 |
Colorectal Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
EphA2, a member of the Eph receptor tyrosine kinases family, is an important regulator of tumor initiation, neovascularization, and metastasis in a wide range of epithelial and mesenchymal cancers; however, its role in colorectal cancer recurrence and progression is unclear.
|
26283684 |
2016 |
Colorectal Carcinoma
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to determine the relation of EPH tyrosine kinase receptor B2 (EPHB2) A9 region mutation and microsatellite instability (MSI); and to analyze their influence in prognosis of patients with sporadic colorectal cancer (CRC).
|
24222164 |
2013 |
Colorectal Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
However, other Eph gene expression was lost in individual CRCs compared to the corresponding normal, EphA7 being a striking example.
|
21852108 |
2012 |
Colorectal Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Our data indicate that the EphA1 may play different roles during the different stages of colorectal carcinoma progression.odern Pathology (2009) 22, 151-160; doi:10.1038/modpathol.2008.188; published online 14 November 2008.
|
19011600 |
2009 |
Colorectal Carcinoma
|
0.380 |
Biomarker
|
disease |
CTD_human |
Intriguingly, EphA1 over-expression was more prevalent in stage II compared to stage III CRCs (P=0.02).
|
19277044 |
2009 |
Colorectal Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Intriguingly, EphA1 over-expression was more prevalent in stage II compared to stage III CRCs (P=0.02).
|
19277044 |
2009 |